- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07603375
Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma (TNT Esophagus)
A Single-arm Study of Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma
The goal of this trial is to learn if adding consolidative chemotherapy to routine chemoradiation can better control both local recurrence and metastasis and reduce the need for surgical intervention.
연구 개요
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Clinical Trials Office
- 전화번호: (919) 668-3726
- 이메일: RadOnc-Clinical_Trials@dm.duke.edu
연구 장소
-
-
North Carolina
-
Durham, North Carolina, 미국, 27710
- 모병
- Duke University Medical Center
-
수석 연구원:
- Manisha Palta, MD
-
연락하다:
- Kaitlin Bailey, RN BSN OCN
- 전화번호: (919) 668-3726
- 이메일: RadOnc-Clinical_Trials@dm.duke.edu
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Subject must be able to provide study specific informed consent prior to study entry
- Must be newly diagnosed, histologically proven diagnosis of adenocarcinoma of the thoracic esophagus or gastroesophageal junction (Siewert I-II);
- Stage II-IVA, excluding T4b, according to the American Joint Committee on Cancer (AJCC) 8th edition;
- Complete history and physical examination within 21 days of signing consent;
- Staging whole-body FDG-PET/CT (fluorodeoxyglucose-positron emission tomography/computed tomography) scan with or without contrast (preferred) or chest/abdominal (CT with contrast) confirming there is no evidence of metastatic disease must be obtained within 45 days of study enrollment
- ECOG (Eastern Cooperative Oncology Group) performance status of 0-2
- Subjects must be appropriate candidates for planned chemoradiation (concurrent carboplatin/paclitaxel) and chemotherapy (FLOT, m-FOLFOX-6) as determined by the treating radiation oncologist, medical oncologist, and surgical oncologist.
- Adequate hematologic, renal, and hepatic function within 14 days of initiation of therapy
Exclusion Criteria:
-
Cervical esophageal cancers arising 15-18 cm from the incisors.
-
Esophageal squamous cell carcinoma.
-
Patients with T4b disease according to the AJCC 8th Edition.
-
Definitive clinical or radiologic evidence of metastatic disease.
-
Has had prior systemic therapy or radiation therapy for the current diagnosis.
-
Prior thoracic radiotherapy for any reason that would result in overlap of radiation therapy fields; all patients with prior radiotherapy must be reviewed by the PI to determine if patient is eligible.
-
Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer
-
Severe, active co-morbidity defined as follows:
- Active uncontrolled infection requiring IV antibiotics;
- Pregnant and/or nursing subjects;
- HIV positive with CD4 count < 200 cells/microliter. Note that subjects who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count ≥ 200 cells/microliter within 30 days prior to registration. Note also that HIV testing is not required for eligibility for this protocol. This exclusion criterion is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
-
Has a history or current evidence of physical or physiological contraindication to participation in this study, at the discretion of the treating investigator.
-
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Chemoradiation with consolidative chemotherapy
Participants will receive a standard course of chemoradiation followed by consolidative chemotherapy (FOLFOX regimen at the treating physician's discretion). |
Modified-FOLFOX-6 or FLOT (Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel) |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of participants with Clinical complete response (cCR)
기간: approximately 36 weeks
|
cCR defined as absence of malignancy on endoscopic biopsies obtained at the time of reassessment following neoadjuvant therapy |
approximately 36 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of participants who complete both chemoradiation and chemotherapy
기간: approximately 36 weeks
|
approximately 36 weeks
|
|
|
Number of participants with pathologic complete response (pCR)
기간: approximately 36 weeks
|
Pathologic complete response (pCR) is defined as absence of detectable tumor of esophagectomy tissues. |
approximately 36 weeks
|
|
Number of participants with local control
기간: up to 5 years
|
Local control in participants achieving clinical complete remission (cCR) estimated using the Kaplan-Meier method. cCR is defined as the disappearance of all detectable signs and symptoms of a disease, such as cancer, have completely disappeared. |
up to 5 years
|
|
Number of participants with Disease free survival
기간: up to 5 years
|
Disease free survival in participants achieving cCR estimated using the Kaplan-Meier method. cCR is defined as the disappearance of all detectable signs and symptoms of a disease, such as cancer, have completely disappeared. |
up to 5 years
|
|
Time to distant metastasis
기간: up to 5 years
|
Time to distant metastasis in participants achieving cCR estimated using the Kaplan-Meier method. cCR is defined as the disappearance of all detectable signs and symptoms of a disease, such as cancer, have completely disappeared. |
up to 5 years
|
|
Overall survival
기간: up to 5 years
|
Measured in participants achieving cCR and estimated using the Kaplan-Meier method. cCR is defined as the disappearance of all detectable signs and symptoms of a disease, such as cancer, have completely disappeared. |
up to 5 years
|
|
Number of participants with Local control
기간: up to 5 years
|
Measured in participants achieving pCR and estimated using the Kaplan-Meier method. pCR is defined as absence of detectable tumor of esophagectomy tissues. |
up to 5 years
|
|
Disease free survival
기간: up to 5 years
|
Disease free survival in participants achieving pCR. pCR is defined as absence of detectable tumor of esophagectomy tissues. |
up to 5 years
|
|
Time to distant metastasis
기간: up to 5 years
|
Time to distant metastasis in participants achieving pCR estimated using the Kaplan-Meier method. pCR is defined as absence of detectable tumor of esophagectomy tissues. |
up to 5 years
|
|
Overall survival
기간: up to 5 years
|
Measured in participants achieving pCR and estimated using the Kaplan-Meier method. pCR is defined as absence of detectable tumor of esophagectomy tissues. |
up to 5 years
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Manisha Palta, MD, Duke Health
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- Pro00120182
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Data may be shared 6 months after publication or as required by the journal
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .